A Propensity Score Analysis Shows that Empirical Treatment with Linezolid Does Not Increase the Thirty-Day Mortality Rate in Patients with Gram-Negative Bacteremia

The role of linezolid in empirical therapy of suspected bacteremia remains unclear. The aim of this study was to evaluate the influence of empirical use of linezolid or glycopeptides in addition to other antibiotics on the 30-day mortality rates in patients with Gram-negative bacteremia. For this pu...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Antimicrob Agents Chemother
Autors principals: Ternavasio-de la Vega, Hugo-Guillermo, Mateos-Díaz, Ana-María, Martinez, Jose-Antonio, Almela, Manel, Cobos-Trigueros, Nazaret, Morata, Laura, De-la-Calle, Cristina, Sala, Marta, Mensa, Josep, Marcos, Miguel, Soriano, Alex
Format: Artigo
Idioma:Inglês
Publicat: American Society for Microbiology 2014
Matèries:
Clinical Therapeutics
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4249502/
https://ncbi.nlm.nih.gov/pubmed/25199780
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.03796-14
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars